M
Marcus O. Butler
Researcher at Harvard University
Publications - 20
Citations - 2571
Marcus O. Butler is an academic researcher from Harvard University. The author has contributed to research in topics: Cytotoxic T cell & Antigen-presenting cell. The author has an hindex of 15, co-authored 20 publications receiving 2435 citations. Previous affiliations of Marcus O. Butler include Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
F. Stephen Hodi,Martin C. Mihm,Robert J. Soiffer,Frank G. Haluska,Marcus O. Butler,Michael V. Seiden,Thomas A. Davis,Rochele Henry-Spires,Suzanne MacRae,Ann Willman,Robert F. Padera,Michael T. Jaklitsch,Sridhar Shankar,Teresa C. Chen,Alan J. Korman,James P. Allison,Glenn Dranoff +16 more
TL;DR: Findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients.
Journal ArticleDOI
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. Stephen Hodi,Marcus O. Butler,Darryl A. Oble,Michael V. Seiden,Michael V. Seiden,Frank G. Haluska,Andrea Kruse,Suzanne MacRae,Marybeth Nelson,Christine Canning,Israel Lowy,Alan J. Korman,David B. Lautz,Sara Russell,Michael T. Jaklitsch,Nikhil H. Ramaiya,Teresa C. Chen,Donna Neuberg,James P. Allison,Martin C. Mihm,Glenn Dranoff +20 more
TL;DR: It is shown that periodic infusions of anti-CTLA-4 antibodies after vaccination with irradiated, autologous tumor cells engineered to secrete GM-CSF (GVAX) generate clinically meaningful antitumor immunity without grade 3 or 4 toxicity in a majority of metastatic melanoma patients.
Journal ArticleDOI
Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.
Michael von Bergwelt-Baildon,Robert H. Vonderheide,Britta Maecker,Naoto Hirano,Karen S. Anderson,Marcus O. Butler,Zhinan Xia,Wan Y. Zeng,Kai W. Wucherpfennig,Lee M. Nadler,Joachim L. Schultze,Joachim L. Schultze +11 more
TL;DR: This work demonstrates that CD40-B cells from healthy donors and cancer patients are fully functional and equally expanded in long-term cultures, and are an excellent source of professional APCs for immune assessment, antigen discovery, and antigen-specific immunotherapy.
Journal ArticleDOI
Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity.
Naoto Hirano,Naoto Hirano,Marcus O. Butler,Marcus O. Butler,Zhinan Xia,Zhinan Xia,Sascha Ansén,Sascha Ansén,Michael von Bergwelt-Baildon,Michael von Bergwelt-Baildon,Donna Neuberg,Donna Neuberg,Gordon J. Freeman,Gordon J. Freeman,Lee M. Nadler,Lee M. Nadler +15 more
TL;DR: It is demonstrated that the engagement of the CD83 ligand (CD83L) preferentially enriches and significantly amplifies the number of antigen-specific CD8+ T cells and could be exploited to generate long-lived antigen- specific cytotoxic T cells for the treatment of cancer and infection.
Journal ArticleDOI
Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell
Marcus O. Butler,Jeng Shin Lee,Sascha Ansén,Donna Neuberg,F. Stephen Hodi,Andrew P. Murray,Linda Drury,Alla Berezovskaya,Richard C. Mulligan,Lee M. Nadler,Naoto Hirano +10 more
TL;DR: Clinical grade aAPC33, produced under current Good Manufacturing Practices guidelines, generated sufficient numbers of CTL within a short period of time, and these CTL specifically lysed a variety of melanoma tumor lines naturally expressing a target melanoma antigen.